Pharm

CD22 Monoclonal Antibody

CD22 Monoclonal Antibody, CD22 Antigen, Moxetumomab pasudotox-tdfk, Lumoxiti, Inotuzumab Ozogamicin, Besponsa

CD22
1. CD22 is a B Cell lectin and adhesion molecule
2. CD22 is involved in cell signaling and adhesion to Monocytes and T-Cells
CD22 Monoclonal Antibody
1. Conjugate antibodies that deliver cytotoxic drugs to CD22 positive cancer cells

Moxetumomab pasudotox-tdfk (Lumoxiti)
1. Conjugated Monoclonal Antibody that delivers the cytotoxic drug Pseudomonas exotoxin A to cancer cells
2. Avoid in severe Renal Insufficiency (eGFR <30 ml/min)
3. Used in Hairy Cell Leukemia
4. Risks of Hemolytic Uremic Syndrome, capillary leak syndrome, Nephrotoxicity, Electrolyte abnormalities
Inotuzumab Ozogamicin (Besponsa)
1. Conjugated Monoclonal Antibody that delivers the cytotoxic drug calicheamicin to cancer cells
2. Used against B Cell precursors in Acute Lymphoblastic Leukemia
3. Risks of hepatotoxicity and hepatic veno-occlusive disease

Hemolytic Uremic Syndrome
Capillary leak syndrome
Nephrotoxicity
1. Obtain Renal Function testing before each dose
Infusion Reaction
1. Premedicate
Electrolyte abnormalities
1. Obtain Electrolytes before each dose and at 8 days after dose
Other common adverse effects
1. Gastrointestinal (Nausea, Diarrhea, Constipation)
2. Headache
3. Fever
4. Anemia

Infusion Reactions
QTc Prolongation
Hepatotoxicity
1. Includes hepatic veno-occlusive disease (sinusoidal obstruction)
2. Increased transaminases, GGT, and Serum Bilirubin
Myelosuppression
Other common adverse effects
1. Fever
2. Nausea or Vomiting

Avoid in Lactation
Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
1. Use reliable Contraception
Monitoring
1. Renal Function tests
2. Serum Electrolytes (including Serum Calcium, Serum Phosphorus)
3. Liver Function Tests (LFTs)